4D Molecular Therapeutics Inc. Stock Price, News & Analysis

4D Molecular Therapeutics (Nasdaq: FDMT) has appointed Carolyne Zimmermann as the new Chief Business Officer. Zimmermann brings nearly 20 years of experience in life sciences from her roles at Johnson & Johnson Innovation and Novartis Pharmaceuticals. The appointment is aimed at leveraging her expertise in corporate development to enhance the company's gene therapy platform, Therapeutic Vector Evolution. 4DMT focuses on developing targeted gene therapies in ophthalmology, cardiology, and pulmonology, currently running three clinical trials for various genetic conditions.

4D Molecular Therapeutics (Nasdaq: FDMT) has announced participation in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 2:30 p.m. PT. This event will feature a fireside chat available via a live audio webcast on the company's website, with a replay accessible for two weeks after the event. 4DMT focuses on advancing gene therapy through its Therapeutic Vector Evolution platform, targeting areas like ophthalmology and cardiology, with ongoing clinical trials for multiple diseases including XLRP, choroideremia, and Fabry disease.

4D Molecular Therapeutics (FDMT) reported its Q1 2021 financial results, marking a notable progress as a public company. Cash and cash equivalents stood at $259.9 million, sufficient to fund operations into mid-2023. However, total revenue decreased to $2.0 million from $3.5 million year-over-year, largely due to reduced revenue from collaborations. R&D expenses decreased slightly to $12.8 million, while G&A expenses rose to $5.5 million. The net loss increased to $16.4 million from $13.2 million in the previous year.

4D Molecular Therapeutics (Nasdaq: FDMT) has announced promising preclinical data for its dual transgene gene therapy, 4D-150, aimed at treating wet AMD and DME. Presenting at the ASGCT Annual Meeting, the therapy demonstrated complete suppression of CNV lesions in non-human primates at the lowest tested dose of 1E11 vg/eye. The acute biodistribution study showed significant ocular aflibercept expression with no adverse ocular effects. This novel approach targets multiple VEGF family members, potentially enhancing efficacy in patients resistant to existing treatments.

4D Molecular Therapeutics (Nasdaq: FDMT) announced a collaboration with UC Berkeley to enhance its Therapeutic Vector Evolution platform using machine learning. This partnership aims to expand the company’s vector patent portfolio and improve bioinformatics capabilities. 4DMT boasts the largest biodistribution datasets and has conducted over 15 vector selection programs. The company is developing several product candidates in clinical trials, focusing on ophthalmology, cardiology, and pulmonology, with safety and efficacy yet to be determined by regulatory authorities.

4D Molecular Therapeutics (Nasdaq: FDMT) announced its participation in the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 2:00 p.m. PT. The presentation will be accessible via a live audio webcast on the company’s website, with a replay available for two weeks post-event.

The company focuses on targeted gene therapy using its Therapeutic Vector Evolution platform. Currently, 4DMT is conducting three clinical trials: 4D-125 for XLRP, 4D-110 for choroideremia, and 4D-310 for Fabry disease.

4D Molecular Therapeutics (Nasdaq: FDMT) announced that abstracts for three of its gene therapy product candidates have been accepted for oral presentations at two significant medical conferences. The presentations will focus on:

• 4D-150 for wet AMD and DME, highlighting its anti-angiogenic mechanisms and preclinical efficacy.
• 4D-310 for Fabry disease.
• 4D-710 for cystic fibrosis lung disease.

The presentations are scheduled for the ASGCT Annual Meeting from May 11-14 and the ATS International Conference from May 14-19, 2021.

On March 25, 2021, 4D Molecular Therapeutics (FDMT) reported significant operational developments and financial results for the year ending December 31, 2020. The first patient was dosed in the Phase 1/2 trial for 4D-310 targeting Fabry disease. Additionally, the company completed dose escalation for 4D-125 and 4D-110, both well-tolerated. Financially, cash stood at approximately $277 million, a substantial increase from $49.7 million in 2019, while revenue rose to $13.6 million. However, the company recorded a net loss of $56.7 million, up from $49.3 million the prior year.

4D Molecular Therapeutics announced the dosing of the first patient in its Phase 1/2 clinical trial of 4D-310, aimed at treating Fabry disease, a condition with significant unmet medical needs. The trial will evaluate safety, tolerability, and activity of the therapy, with enrollment set for up to 18 patients. 4D-310 employs a novel dual mechanism targeting AGA enzyme activity in blood and affected tissues, addressing limitations of current enzyme replacement therapies. This advancement highlights the company's commitment to innovative gene therapies.